Assuming that Advair will face competition from a substitutable generic in the US by mid-2017, GSK guided for flat to a slight decline in Core EPS at constant exchange rates. The stock is trading at a discount to five years average historical P/E vs. peers and some potential source of earnings upside is expected in 2017.
Category: Mylan Laboratories
Federal Trade Commission investigating Mylan over EpiPen
Mylan NV has received a request for information from the Federal Trade Commission in order to launch a preliminary investigation over whether the company violated antitrust laws over its pricing of the EpiPen, a popular allergy drug, according to a report by Bloomberg.
CVS generic competitor to EpiPen, sold at a 6th the price
Health insurance giant Cigna said it will no longer cover Mylan’s EpiPen, which had been subject the a controversial price hike in 2016. Amid the negative press, Mylan ended up offering a coupon to reduce the drug’s price.
CVS puts out generic competitor to EpiPen at a 6th the price
… generic version of Adrenaclick, a lesser-known treatment compared to EpiPen, which can cost more than $600. CVS Health Corp., the nation’s second-largest drugstore chain, says it cut the price it charges for the generic version of Adrenaclick nearly …
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and…
… pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com largest and fully-integrated, innovation-led biopharmaceutical …
Mylan’s EpiPen Sales Plan: Schools Today, Everywhere Tomorrow
… to supply the EpiPen in case it’s needed,” Minear said. “It’s a lifesaving thing.” Mylan said its pharmacy, Mylan Health Management, would be used to distribute EpiPens only to entities and not to individuals, according to the company’s pharmacy …
EpiPen price outrage could bring more changes under Donald Trump
… their own, saying Mr. Trump should follow through on his promise to slash drug prices by allowing the Department of Health and Human Services to negotiate drug prices under Medicare and speeding generics to the market, among other reforms. Until Mr. …
Mylan announces U.S. launch of generic Concerta Tablets
… than 240 ANDAs pending FDA approval representing approximately $95.6 billion in annual brand sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $32.5 billion in annual brand …
Mylan launches generic Zovia in U.S.
Mylan has announced the launch of a generic version of Zovia , a pregnancy preventative, in the U.S. The product — Ethyniol Diacetate and Ethinyl Estradiol tablets — was found to be bioequivalent to Zovia, and subsidiary Jai Pharma got FDA approval for its abbreviated new drug application.